Acarix A/S - Asset Resilience Ratio
Acarix A/S (ACARIX) has an Asset Resilience Ratio of 37.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Acarix A/S to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Acarix A/S's Asset Resilience Ratio has changed over time. See net asset quality index of Acarix A/S to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Acarix A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Acarix A/S (ACARIX) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr18.27 Million | 37.81% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr18.27 Million | 37.81% |
Asset Resilience Insights
- Very High Liquidity: Acarix A/S maintains exceptional liquid asset reserves at 37.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Acarix A/S Industry Peers by Asset Resilience Ratio
Compare Acarix A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for Acarix A/S (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Acarix A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.19% | Skr152.00K ≈ $16.36K |
Skr80.76 Million ≈ $8.69 Million |
-0.05pp |
| 2023-12-31 | 0.23% | Skr147.00K ≈ $15.82K |
Skr62.88 Million ≈ $6.77 Million |
-16.04pp |
| 2022-12-31 | 16.28% | Skr11.31 Million ≈ $1.22 Million |
Skr69.48 Million ≈ $7.48 Million |
+2.79pp |
| 2021-12-31 | 13.49% | Skr16.00 Million ≈ $1.72 Million |
Skr118.60 Million ≈ $12.76 Million |
+13.27pp |
| 2020-12-31 | 0.22% | Skr195.00K ≈ $20.99K |
Skr89.95 Million ≈ $9.68 Million |
-0.07pp |
| 2019-12-31 | 0.28% | Skr234.00K ≈ $25.18K |
Skr82.98 Million ≈ $8.93 Million |
-68.19pp |
| 2018-12-31 | 68.48% | Skr65.19 Million ≈ $7.02 Million |
Skr95.20 Million ≈ $10.24 Million |
-8.79pp |
| 2017-12-31 | 77.27% | Skr103.58 Million ≈ $11.15 Million |
Skr134.06 Million ≈ $14.43 Million |
-6.97pp |
| 2016-12-31 | 84.24% | Skr145.97 Million ≈ $15.71 Million |
Skr173.29 Million ≈ $18.65 Million |
+83.89pp |
| 2015-12-31 | 0.35% | Skr54.00K ≈ $5.81K |
Skr15.58 Million ≈ $1.68 Million |
-- |
About Acarix A/S
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauri… Read more